A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer

NCT07591597 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Neoplasms
Microsatellite Stable / Proficient Mismatch Repair Colorectal Cancer

Interventions

BIOLOGICAL: S-531011
DRUG: Fruquintinib
BIOLOGICAL: Pembrolizumab

Sponsor

National Cancer Center Hospital East

Collaborators

[object Object]